Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
All News
Article
One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.
Article
The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.
Article
EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.
Article
The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.
Dr. John Cush
Tweet
Danish registry study of 1,356 psoriasis and 370 PsA pts shows increased odd of coronary disease by CT Calcium scores - psoriasis w CACS ≥ 400 OR 1.25 (1.04-1.50); PsA CACS>0 OR 1.28 (1.00-1.64). Nearly a 49% incr risk in PSO (HR 1.49) https://t.co/jQSAV66TAi
Dr. John Cush
Tweet
Cross-sectional study RA and PFTs, shows among 2,008 cases, RA was assoc w/ increased odds of restrictive (OR 1.36) & obstructive patterns (OR 1.21) not explained by confounders like smoking. RA had lower predicted FEV1, FVC, FEV1/FVC https://t.co/cVxatLQCG4
Dr. John Cush
Tweet
Very cool article in Nature - Tissues, not blood, are where immune cells function https://t.co/NCBSBWhjTX
Dr. John Cush
Tweet
Meet the #SLEEducatorsNetwork in this disease education series where leading rheumatologists and nephrologists share their perspectives on lupus nephritis.
Sponsored by GSK US Medical Affairs
https://t.co/H9BqP9bW4i https://t.co/5AW1IRhBrC
Dr. John Cush
Tweet
RNL 2021: Best of times, worst of times (Keynote): Dr. Iain McInnes
Dr. Iain McInnes presents his keynote lecture, Best of Times, Worst of Times..., at RheumNow Live 2021.
https://t.co/v3hOYuJZad
Dr. John Cush
Tweet
We'll be covering EULAR 2021 next week. Look for our coverage from June 3-8. https://t.co/YPNx8MBRn7
Dr. John Cush
Tweet
Unable to attend the Tuesday Night Rheumatology on RA and vaccines? Watch the replay below.
https://t.co/hUFTjDAnsg https://t.co/ywCRjqg1To
Dr. John Cush
Tweet
Virtual DDW meeting this wk reports claims data comparing IBD to IBD with RA - IBD alone vs IBD w/ RA dx w/ more depression (21% vs 84%), anxiety (20% vs 47%). IBD w/ RA had more depression (OR 7.2); anxiety (OR, 1.25;) or both (OR, 2.3) https://t.co/B78xcJw584
Dr. John Cush
Tweet
News Feature: CV Risk Decreased with Certain DMARDs in Rheumatoid Arthritis
A large prospective cohort study examined the comparative risks of CVD in patients with RA and found that, MTX, ABA & TNFi use were associated w/ a decreased risk of CV events.
https://t.co/uQbtB76Hgy https://t.co/ftc5ys9C58
Dr. John Cush
Tweet
Mark your calendars--we'll be covering EULAR 2021 from June 3 through June 8. Over coverage will include new articles, videos, polls and more. https://t.co/LksbsK2TW2
Dr. John Cush
Tweet
Interesting report of 27 pts w/ Jo-1 anti-synthetase syndrome shows that only 4 had classic triad at presentation. 7 patients presented with polyarthritis, 6/7 initially Dx as #RA, Time gap from RA to antisynthetase dx was 3 to 20 years. https://t.co/IMgk3VTr0c
Dr. John Cush
Tweet
Dr. Samir V. Parikh from the #SLEEducatorsNetwork discusses the major treatment goals for lupus nephritis and the broader needs of the patient in this program- Defining Treatment Goals for Lupus Nephritis.
Sponsored by GSK US Medical Affairs
https://t.co/f2Y707YDJr https://t.co/lsYDVFWSCS
Dr. John Cush
Tweet
Good Free 2 part series on Juvenile Fibromyalgia: a chronic diffuse musculoskeletal aching and pain syndrome that may be hard to distinguish from complex regional pain syndrome (CRPS) (ALWAYS CHECK FOR HYPERMOBILITY in Kids) https://t.co/EPmmGVNW63 https://t.co/aP6QHT7tiM
Dr. John Cush
Tweet
Preliminary results from 600 pt SAVE-MORE trial in severe COVID, anakinra + standard-of-care was 55% better than SOC in preventing death or respiratory failure; and improving Hosp Discharge by 4 days. Anakinra Rx 100mg/day up to 10 days https://t.co/vbpUMQjC1o
Dr. John Cush
Tweet
Popular Read: Little Effect with Multimodal Treatment of CMC1 Osteoarthritis
https://t.co/6SnJYOK6nu https://t.co/ldTQRujshq
